Christopher Pleyer, MD

Dr. Pleyer's current area of focus at the NIH is understanding vaccine responses and changes in the immune system following therapy of chronic lymphocytic leukemia (CLL) with novel oral therapies. He is also the Associate Program Director for the combined NCI/NHLBI Hematology & Oncology fellowship program.

Dr. Pleyer received his M.D. with summa cum laude from the Paracelsus Medical University, Austria in 2012. He completed his internal medicine residency at the Cleveland Clinic in 2016 and fellowship in hematology and medical oncology at the National Institutes of Health in 2019. He received an MBA from the Johns Hopkins University Carey Business School in 2023. Dr. Pleyer is board certified in internal medicine, medical oncology, and hematology.

Publications:

BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL

COVID-19 vaccines for patients with haematological conditions

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib